Takeaway
A model combining plasma levels of neurofilament light chain (NfL) and scores of two cognitive tests could reliably predict fast decline in patients with Alzheimer’s disease (AD).
Why this matters
Faster disease progression in patients with AD is associated with higher risks of mortality, autonomy loss, and institutionalization.
Accelerated decline occurs in approximately 30% of patients, but it is currently unclear which disease and/or patient variables are associated with this phenomenon.